Kevin Reyna

[Excellence in Oncology Care - EIOC @EiocOncology]

Approved by the FDA and published in the NEJM. A paradigm shift for the adjuvant management of renal cell cancer.

#KidneyCancer #Oncology #FDAApproval #NEJM

[Luiza Pamela Beato @luiza_beato]

Crown trial!
Even after 7 years, the median PFS has still not been reached!!!

The lucky pill!! 💊 🍀🌟🔆

[Dr Rishabh Jain @DrRishabhOnco]

THE 5 BIGGEST GYNAE ONCOLOGY TRIALS OF #ASCO26

1️⃣ RUBY
Long-term survival modeling in dMMR EC
⭐ Durable remission plateau?

2️⃣ NRG-GY018
OS update for pembrolizumab + chemo
⭐ Does frontline IO change long-term survival?

3️⃣ ROSELLA
Relacorilant in platinum-resistant ovarian cancer
⭐ Which patients benefit most?

4️⃣ CHIPRO
Chiauranib + paclitaxel in resistant ovarian cancer
⭐ Multi-kinase strategy enters Phase III

5️⃣ MIROVA / AGO-OVAR 2.34
Mirvetuximab in FRα-high ovarian cancer
⭐ ADCs move earlier

#GynOnc #OncTwitter #ASCO26 #OvarianCancer #EndometrialCancer #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert

[Dr Rishabh Jain @DrRishabhOnco]

🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26

Chicago is loaded this year.

From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇

🩷 HR+ / HER2- DISEASE

1️⃣ persevERA BC (LBA1006)
Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease

Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit.

2️⃣ SERENA-6 (LBA1007)
Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression

Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting.

3️⃣ VIKTORIA-1
Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression

Huge unmet-need population.
Post-CDK4/6 sequencing remains one of the biggest HR+ questions.

4️⃣ lidERA BC (Abstract 502)
Adjuvant giredestrant in early ER+/HER2- disease

Moving oral SERDs into curative-intent therapy.

5️⃣ FOURLIGHT-2 (Abstract 1042)
Next-gen CDK4-selective inhibition with atirmociclib + letrozole

Can we reduce neutropenia while preserving efficacy?

🔥 TNBC & ADC ERA

6️⃣ ASCENT-04 (LBA1000)
Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC

Could ADC + IO combinations become the frontline standard?

7️⃣ TROPION-Breast02
Dato-DXd vs chemotherapy in metastatic TNBC

A major test of the “ADC-first” paradigm.

🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS

8️⃣ KN026-004 (LBA660)
Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy

Watch the pCR data carefully.

9️⃣ I-SPY 2.2 (LBA514)
Rilvegostomig + T-DXd in high-risk HER2-negative disease

IO + ADC combinations continue moving earlier.

🔟 DESTINY-Breast05 Update
Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease

Which breast abstract are you watching most closely?

#BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco @myesmo @esmo_open @OncoAlert @OncBrothers

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO

From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming.

Which one are you watching?

@OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

[Dr Amol Akhade @SuyogCancer]

What are plenary sessions for ASCO 2026 ?
Titles are just out
Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri

[Dr Amol Akhade @SuyogCancer]

Daraxonrasib: monotherapy vs + chemo in 1L mPDAC 🚀
RAS-mutant mPDAC:
Comparison of monotherapy vs combination
🔹 Monotherapy (n=40; eval n=35)
• ORR 51% | DCR 97%
• 6-mo PFS 71%
• ctDNA clearance 57% (n=28)

🔹 + GnP (gemcitabine + nab-paclitaxel) (n=40; eval n=39)
• ORR 59% | DCR 92%
• 6-mo PFS 84%
• ctDNA clearance 61% (n=28)
👉 Signal: is chemo adding much to this drug ? 🤔 @GIcancerDoc @Erman_Akkus @MyriamChalabi @OncoAlert @MedwatchKate
#PancreaticCancer #AACR26

[Anirban Maitra @Aiims1742]

🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!

AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O

[Pablo Jiménez @PaulJiL]

#ADC #B7H4

Targeting B7-H4 is beginning to show a growing number of positive signals✅, especially when used with ADCs, in several tumors
-Adenoid Cystic Ca
-Platinum resistant ovarian Ca
-TN breast Ca

The "relative" of PD-L1 (aka B7-H1🤯)
@OncoAlert @brunolarvol

[Thor Halfdanarson @OncoThor]

Time for another NET talk - this time on sequencing of systemic therapy. Another excellent @MayoMedEd offering. If you are looking for a good course in pretty much anything in Med Ed, check them out. They have a huge selection of quality courses, not just in oncology.

So how to we select initial therapy for advanced NETs when resection or other regional therapy is not a good option...? Below are some thoughts, as always open to criticism and and comments (snarky comments also welcomed if you feel so inclined...).

Come join us for future Mayo Clinic conferences!

[Angela Lamarca @DrAngelaLamarca]

Cabozantinib in #G3NEN (Ki67 20-60%) at #ENETS2026 @ENETS_ORG

N=45

PFS 8.53mo
OS 18.8mo

ORR 22%

[Oscar Tahuahua @OscarTahuahua]

Retrospective real-world clinicogenomic study in @Nature

5893 pts with mCRPC
37% HRR pathogenic variants.
13% BRCA1/2.

389 received olaparib:

BRCA2: median OS 17.5 mo
BRCA1: 8.1 mo
HR 2.23 (P=0.008)
BRCA1 clearly worse.

Within BRCA2, subtype defines benefit ⚠️

BRCA2 loss: median OS 24.3 mo
HR 0.42 (P<0.001)

This is intra-BRCA functional heterogeneity ‼️

Not all BRCA alterations are biologically or therapeutically equivalent.
https://t.co/EVyVPFf7HN @OncoAlert

[Tom Powles @tompowles1]

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

[Yakup Ergün @dr_yakupergun]

Rezatapopt: p53 reactivator!
A target we’ve talked about for years — once thought impossible.

TP53 Y220C may define a small patient subset,
but it proves a big point:
mutant p53 can be restored.

A paradigm-shifting proof!
https://t.co/m91o14ZPHG

[Sumanta K. Pal, MD, FASCO @montypal]

Brilliant overview of studies to look out for as we all head into #GU26. @DrChoueiri @neerajaiims @tompowles1 @brian_rini @motzermd @shilpaonc @apolo_andrea @TDorffOnc @kidneycan @KidneyCancer @BladderCancerUS

[GEIS @GrupoGeis]

📄Nueva publicación internacional liderada por Javier Martin-Broto con los primeros resultados del registro SELNET(SAR-TRACK)
🔍Analiza la calidad del manejo del sarcoma en Iberoamérica y la necesidad de atención multidisciplinar y centros de referencia
🔗 https://t.co/9OO9Q3f4O1

[Luisa Rivero @Luisa_RiveroZ]

Delighted and beyond excited! Amazing team @KevReyp @OscarTahuahua along our professors and mentors
#ESMO2025 here we go!

[Oscar Tahuahua @OscarTahuahua]

CUP is 2–5% of cancers but causes the 4th most cancer deaths. ⚠️

While tissue of origin can guide treatment, most patients see no clear benefit. ~33% have actionable mutations, targeted therapy won’t help all, but for some, it could change everything.
https://t.co/F1vwqBiz6B

[Dr Amol Akhade @SuyogCancer]

🆕 FDA grants accelerated approval to Dato-DXd for EGFR-mutated NSCLC post-TKI + chemo 👏
But what’s the full picture? 🤔🧵
🔹 Based on 117 pts pooled from TROPION-Lung01 & Lung05
🔹 ORR: 43% | PFS: 5.8 mo | OS: 15.6 mo 📊
🔹 Prior osimertinib in 82% of pts
🔹 Common tox:
Stomatitis (69% any grade) 👄
Ocular events (32%) 👁️
ILD (4%) ☁️
✅ Signal of activity in a high-need population
⚠️ But:
No control arm
No stratification by TROP2 or EGFR mutation subtype
Limited CNS data 🧠
Accelerated based on surrogate endpoints (ORR/DOR)
📌 Dato-DXd brings hope, but confirmatory data is essential.
A step forward—but we must walk with scientific caution 👣
#LungCancer #EGFR #NSCLC #OncoTwitter #ADC @OncoAlert @brunolarvol

[Kevin Reyna @KevReyp]

@SuyogCancer 7471223205

Add me